CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
 Chief Technology Officer Profile

Similar Companies

Oncopeptides AB

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers.

OMEGA ALPHA PHARMACEUTICALS

OMEGA ALPHA PHARMACEUTICALS INC. is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onco360 Pharmacy

Onco360 provides industry-leading Oncology Pharmacy services for Patients, Physicians, Pharma, Payers, & Hospitals. Learn more.

Community Intervention Services

Lexigen

Lexigen is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.